EYPT vs REGN

EyePoint Inc has undergone a material positive transformation since the last analysis, with its lead candidate EYP-1901 (now branded VERISERT) for wet AMD achieving accelerated FDA approval in early 2026, following highly positive Phase 3 results in late 2025. This de-risks the primary clinical hurdle, validating EyePoint's Durasert sustained-release technology and suprachoroidal delivery platform...

Regeneron is a high-quality, profitable pharmaceutical giant with robust R&D and strong market positions (e.g., Dupixent). However, its substantial current market capitalization (over $80B) and established, albeit growing, business model make 10x growth within 3-5 years highly improbable. Its catalysts, while significant for continued strong performance, are incremental rather than disruptive enou...